Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

179.9 Selling, general and administrative 452.1 (46.4) - (16.7) 389.0 Loss on sale of product rights 0.3 - - (0.3) - - Reorganization costs 5.0 - - (5.0) - - Integration and acquisition costs 5.3 - (5.3) - - - Depreciation - - - - 30.9 30.9 Total operating expenses 830.7 (62.4) (14.3) (8.7) - 745.3 Operating income 255.4 62.4 14.3 8.7 - 340.8 Interest income 0.3 - - - - 0.3 Interest expense (9.7) - - - - (9.7) Other income/(expense), net 15.6 - - (23.5) - (7.9) Total other income/(expense), net 6.2 - - (23.5) - (17.3) Income before income taxes and equity in earnings of equity method investees 261.6 62.4 14.3 (14.8) - 323.5 Income taxes (69.5)(16.4) (2.9) 9.2 (79.6) Equity in earnings of equity method investees, net of tax 0.8 - - - - 0.8 Net income 192.9 46.0 11.4 (5.6) - 244.7 Impact of convertible debt, net of tax 8.4 - - - - 8.4 Numerator for diluted EPS 201.3 46.0 11.4 (5.6) - 253.1 Weighted average number of shares (millions) - diluted 593.8 - - - - 593.8 Diluted earnings per ADS 101.7c 23.2c 5.8c (2.8c) - 127.9c

The following items are included in Adjustments:

a)Amortization and asset impairments: Impairment of intangible assets ($16.0 million), amortization of intangible assets relating to intellectual property rights acquired ($46.4 million), and tax effect of adjustments;

b)Acquisition and integration activities: Unwind of ABH inventory step-up ($9.0 million), costs associated with the acquisition and integration of ABH ($3.6 million) and integration of Movetis ($1.7 million), and tax effect of adjustments;

c)Divestments, reorganizations and discontinued operations: Accelerated depreciation ($2.2 million) and dual running costs ($1.2 million) on the transfer of manufacturing from Owings Mills to a third party, re-measurement of DAYTRANA contingent consideration to fair value ($0.3 million), reorganization costs ($5.0 million) on the transfer of manufacturing from Owings Mills to a third party
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... four patents to the State Intellectual Property Office ... These applications are patents for a ...
... Ueno, Ltd. announced on July 29 after discussing its R&D policy ... day and determined the R&D items as follows. , , ... ophthalmologic & dermatological fields that are its priority and exclusive areas, ... 1. Development code UF-021 (eye diseases) , , ...
... , , PHILADELPHIA, July 30 eResearchTechnology, Inc. (ERT), ... and other services to the biopharmaceutical, medical device and related industries, announced ... 2009. Unless otherwise noted, all comparative numbers refer to changes from ... , Highlights of the second quarter of 2009 were: ...
Cached Biology Technology:China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 2China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 3R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3ERT Reports Second Quarter 2009 Results 2ERT Reports Second Quarter 2009 Results 3ERT Reports Second Quarter 2009 Results 4ERT Reports Second Quarter 2009 Results 5ERT Reports Second Quarter 2009 Results 6ERT Reports Second Quarter 2009 Results 7ERT Reports Second Quarter 2009 Results 8ERT Reports Second Quarter 2009 Results 9ERT Reports Second Quarter 2009 Results 10ERT Reports Second Quarter 2009 Results 11ERT Reports Second Quarter 2009 Results 12
(Date:8/29/2014)... Until recently, little has been known about what genetic ... team of scientists, one of whom is a University ... showing that genes controlling the development of the brain ... domestication., The study was published Aug. 28 in ... It is online at http://www.sciencemag.org/ ., The domestication ...
(Date:8/29/2014)... available in German . ... organisms is considered the oldest form of communication. Acting ... for example, the sexual attraction between males and females. ... to coordinate reproductive behavior in males and females. Scientists ... the Algarve in Faro, Portugal, and at the Max ...
(Date:8/28/2014)... Invasives is now available from the Lady Bird Johnson ... for identifying harmful non-native plant, insect and other invasive ... States cause about $137 billion in economic and other ... kill native plants and more. , "By having streamlined ... invasive species occur, we,re more likely to catch these ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Ready for mating at the right time 2Ready for mating at the right time 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... called nestin to a particularly deadly form of breast ... earlier detection and better treatment. , In the ... Medical School demonstrate that nestin could represent a selective ... aggressive cancer with similarities to mammary stem cells, the ...
... long term hip replacement surgery may lie in the genes, ... the Rheumatic Diseases. , The researchers analysed genetic variations in ... after hip replacement in the 10 years following surgery. ... “aseptic loosening,?which describes a condition in which the artificial joint ...
... leopard found on the islands of Borneo and Sumatra is ... was originally thought to be the same species as the ... analysis conducted at the U.S. National Cancer Institute shows that ... to the differences between other large cat species like lions, ...
Cached Biology News:Selective marker found to indicate aggressive form of breast cancer 2New species declared: Clouded leopard on Borneo and Sumatra 2
... IT siRNA Tracker Intracellular Localization Kit provides ... and deliver siRNA, of your design, in ... vitro tracking experiments. Subcellular localization and functional ... monitored following introduction of the labeled siRNA ...
... Beacon 2000 instrument can be used as ... 2000 Data Manager Software provides the means ... from the instrument. These data can then ... spreadsheets, such as Microsoft Excel or Lotus ...
... for the study of protein:protein interactions from ... that interact with GST•Tag™, S•Tag™, or ... using affinity resins for the tags, and ... filter. The complexes are eluted with sample ...
... Microarray Kit (V2), 22K is useful for investigating ... Each microarray contains content derived from the ATH1 ... Research (TIGR) and represents 21,500 genes. ... x 3? glass slides each containing an identical ...
Biology Products: